TIL | Instil Bio, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	23.07 - 26.71
52 Week Range	6.08 - 92.00
Beta	1.25
Implied Volatility	576.12%
IV Rank	75.97%
Day's Volume	90,008
Average Volume	301,482
Shares Outstanding	6,525,890
Market Cap	152,444,790
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-03-19

Valuation
Profitability
Growth
Health
P/E Ratio	-2.02
Forward P/E Ratio	-2.97
EPS	-11.56
1YR Price Target	22.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	49
Country	USA
Website	TIL

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using our Co-Stimulatory Antigen Receptor, or CoStAR, platform. The company's lead product candidate, ITIL-168, is an autologous TIL therapy that it is initially developing for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma.

TIL's peers: ACHL, ALGS, ALRN, APTO, ASMB, ATHA, BOLT, PMCB, CHRS, CKPT, CMRX, CNTB, CTMX, GLPG, GLYC, KOD, LBPH, LVTX, LYRA, MEIP, MTEM, NKTR, NLSP, NUVB, NXTC, ONCT, OVID, PRQR, PULM, SPRC, SPRO, SRZN, TBPH, NLTX, VALN, VNDA, QNCX, DOMH

*Chart delayed

Analyzing fundamentals for TIL we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see TIL Fundamentals page.

Watching at TIL technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on TIL Technicals page.